E Fund Management

Mainland China institutional fund managers have increased investments in Hong Kong-listed biotech stocks due to attractive valuations and rising cross-border licensing deals. E Fund Management acquired a 7% stake in Biocytogen Pharmaceuticals by purchasing additional shares.

Mainland Chinese institutional fund managers have increased investments in Hong Kong-listed biotechnology stocks due to attractive valuations and a surge in cross-border licensing deals. E Fund Management, China's largest mutual fund manager, acquired a 7% stake in Biocytogen Pharmaceuticals by purchasing 91,500 shares at HK$46.90 each.

Bloomberg ETF IQ discusses opportunities, risks, and trends in the global exchange traded funds industry. The episode features Anna Paglia of State Street Investment Management, Neil Howe of Heft ETF, and Sylvia Zhang of E Fund Management.

China's fund managers must adhere to new regulatory mandates in the 40 trillion yuan mutual fund industry, making it challenging to improve performance. Major companies like China Asset Management and E Fund Management, along with 10 peers, have pledged compliance with updated investment scopes and benchmarks.